Compare Citius Pharmaceuticals Inc (CTXR) vs Fiverr International Ltd (FVRR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Fiverr International Ltd — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Fiverr International Ltd trades at $11.43 (market cap $397.97M). The key difference: Fiverr International Ltd is far larger — about 27.2× Citius Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| CTXR | FVRR | |
|---|---|---|
Market Cap | $14.64M | $397.97M |
Sector | Health | Industrials |
52-Week High | $1.82 | $26.67 |
52-Week Low | $0.53 | $9.62 |
Enterprise Value | $10.86M | $128.57M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Fiverr International (FVRR) trades at $11.27, up 2.08% today, with a bullish technical signal from moving averages. Revenue grew to $430.91M in 2025, with net income reaching $20.98M and a 4.86% margin. The stock appears undervalued with a P/E of 14.64 and P/S of 0.97. Recent news highlights Fiverr's upcoming Q2 2026 earnings and a surge in demand for AI coding specialists, though the stock remains near its 52-week low, down 66% from its high.
The outlook is mixed: strong profitability metrics and low valuation ratios present a potential opportunity, but risks include declining active buyers, ongoing legal investigations, and volatile cash flows. Analyst consensus leans neutral with 41% buy ratings, suggesting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →
